“We’re very excited to work with the expert team at Anthony Nolan who understand our needs completely,” commented Antoine Espinet, CEO at MicrofluidX.
Anthony Nolan’s Cell Therapy and Laboratory Services have become renowned for sourcing and supplying donor starting materials to the cell and gene therapy industry, helping to transform the life sciences industry. The cells provided by Anthony Nolan for use in this research will be donated by healthy, consenting adult donors for research and manufacturing.
“By partnering with Anthony Nolan we know that the cells we are using to develop our technologies are ethically sourced and of the highest quality,” continued Espinet.
MicrofluidX is a UK-based developer of an innovative bioreactor platform, Cyto EngineTM, designed to address the disconnects between cell biology research and industrialized cell therapy manufacturing. The Cyto EngineTM bioreactors use the principles of microfluidics to seamlessly scale from small-volume research tools to GMO manufacturing capabilities, accelerating the development of next-generation cell and gene therapies.
“As we begin testing the Cyto EngineTM‘s capabilities with our early access partners manufacturing processes we knew we needed a reliable partner to supply the starting material,” said Espinet.
The results from this development will be able to demonstrate the potential benefits MicrofluidX’s bioprocessing technology can bring to accelerate the development and translation of new cell and gene therapies to clinical trials at a significantly lower cost than what current tools can enable.
“Our partnership with MicrofluidX represents a major step in achieving our organisational aim of equity. Our work looks to ensure all patients have the best access to treatment for blood cancers or blood disorders, regardless of background or circumstance. We are optimistic and excited at the prospect of more cost-effective therapies resulting from MicrofluidX’s research, making treatment more accessible for all,” stated Daniel Gibson, Director of Cell & Gene Therapy Services at Anthony Nolan.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.